The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Open accessAbstract
Significance: Improving survival of patients with glioblastoma (GBM) using antiangiogenic therapy remains a challenge. In this study we show that dual blockade of angiopoietin-2 and vascular endothelial growth factor delays tumor growth and enhances survival benefits through reprogramming of tumor-associated macrophages toward an antitumor phenotype as well as by pruning immature tumor vessels. The antitumor immunomodulatory potential of this dual blockade supports clinical testing of this approach for GBM with other immunotherapeutic approaches such as checkpoint blockers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental data indicate that VEGF and ANG2 might cooperate to induce tumour immunosuppression and that this effect might be dependent on the relative levels of these cytokines in the TME35–37”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, ANG2 is co-expressed with VEGF in many human solid tumours, such as glioblastoma35, HCC81, and CRC82”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The overall number of T cells in the tumour mass, however, was unchanged16,35,36.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the therapeutic benefits of dual VEGF–ANG2 blockade seem to be conferred through the lymphoid (for example, in breast and colon tumour models16) and/or myeloid cell populations (in both central nervous system (CNS) and non-CNS tumour models16,35,36,90).”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“reprogramming of pro-tumour, M2-like TAMs towards an anticancer M1 phenotype has been shown to be a major contributor to the therapeutic efficacy of dual antiangiogenic therapy targeting VEGF and ANG2, independent of the tumour model used16,35,36.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationRapid Prototyping of Microfluidic Systems in Poly(dimethylsiloxane)
Duffy, D. C., McDonald, J. C., Schueller, O. J. A., & Whitesides, G. M. (1998) · Analytical Chemistry · doi:10.1021/ac980656z · Cited by 5,288
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
How to measure and predict the molar absorption coefficient of a protein
Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., & Gray, T. (1995) · Protein Science · doi:10.1002/pro.5560041120 · Cited by 3,907
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19990702)82:1<12::AID-IJC3>3.0.CO;2-O · doi:10.1002/(sici)1097-0215(19990702)82:1<12::aid-ijc3>3.0.co;2-o
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationTumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Metadata
- Authors
- Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., Askoxylakis, V., Taylor, J. W., Lu-Emerson, C., Batista, A., Kirkpatrick, N. D., Jung, K., Snuderl, M., Muzikansky, A., Stubenrauch, K. G., Krieter, O., Wakimoto, H., Xu, L., Munn, L. L., Duda, D. G., Fukumura, D., Batchelor, T. T., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Tufts University (US)
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;
- Roche Pharma AG (Germany) (DE)
- ORCID
- Kloepper, Jonas
- Riedemann, Lars
- Amoozgar, Zohreh
- Seano, Giorgio
- Susek, Katharina
- Yu, Veronica
- Dalvie, Nisha
- Datta, Meenal
- Song, Jonathan W.
- Askoxylakis, Vasileios
- Taylor, Jennie W.
- Batista, Ana
- Jung, Keehoon
- Snuderl, Matija
- Muzikansky, Alona
- Stubenrauch, Kay G.
- Krieter, Oliver
- Wakimoto, Hiroaki
- Xu, Lei
- Munn, Lance L.
- Duda, Dan G.
- Fukumura, Dai
- Batchelor, Tracy T.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2016-04-04
- Volume
- 113
- Issue
- 16
- Pages
- 4476-4481
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4843473
- OpenAlex
- W2326749252
- Cited by
- 357
- References
- 69
- Citations by year
- 2026: 8 · 2025: 31 · 2024: 29 · 2023: 38 · 2022: 36 · 2021: 50 · 2020: 39 · 2019: 35 · 2018: 40 · 2017: 35 · 2016: 15
- FWCI
- 21.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- HHS | National Institutes of Health (P50CA165962, P01CA080124, KCA125440, R01CA126642, R35CA197743, R01CA159258, R01CA096915, R01HL106584, S10-RR027070, T32-CA073479, K12CA090354)
- U.S. Department of Defense (W81XWH-10-1-0016)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- glioblastoma, angiopoietin-2, vascular endothelial growth factor, bispecific antibodies, anti-VEGF therapy resistance, tumor-associated macrophages, microglia, tumor immune microenvironment, tumor vasculature, tumor growth inhibition, survival
- MeSH terms
- Animals, Antibodies, Neoplasm, Antineoplastic Agents, Glioblastoma, Humans, Macrophages, Neoplasm Proteins, Neoplasms, Experimental, Ribonuclease, Pancreatic, Antibodies, Bispecific, Xenograft Model Antitumor Assays, Vesicular Transport Proteins, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. https://app.cochat.ai/papers/10.1073/pnas.1525360113
- The paper
- Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., Askoxylakis, V., Taylor, J. W., Lu-Emerson, C., Batista, A., Kirkpatrick, N. D., Jung, K., Snuderl, M., Muzikansky, A., Stubenrauch, K. G., . . . Jain, R. K. (2016). Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1525360113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.